Physician profile
Rolando Izquierdo
NPI 1134138027
$121,285.41
in general payments reported to CMS, 2019-2025
13 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $29K · 2021: $5,825 · 2022: $46K · 2023: $11K · 2024: $711 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,500.00 |
| Food and Beverage | $1,420.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Limacorporate S.P.A. | $104,969.07 | 2019-2024 | Smr Shoulder, Prima |
| Lima USA, INC. | $13,987.22 | 2019-2023 | Smr Shoulder, Lantern Surgical Assistant, Delta Cup |
| Exactech, INC. | $1,039.87 | 2021-2023 | |
| Stryker Corporation | $390.04 | 2022-2025 | Blueprint Patient Specific Instrumentation, Aequalis Flex Revive |
| Arthrex, INC. | $270.00 | 2024-2025 | |
| Horizon Therapeutics Plc | $152.92 | 2019 | |
| Xiros INC | $152.43 | 2022 | |
| Encore Medical, Lp | $151.13 | 2025 | Djo Surgical |
| Linvatec Corporation | $73.84 | 2024 | Biobrace 23mm, Linvatec Shoulder Arthroscopy, Allograft Tissue |
| Oak Med, INC. | $57.50 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $29.92 | 2025 | Exparel |
| Depuy Synthes Sales INC. | $11.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$395,162.09 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Izquierdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.